EU formally approves AMGN’s Prolia for treatment of osteoporosis and treatment of bone loss associated with ADT in non-metastatic prostate cancer: http://finance.yahoo.com/news/ProliaR-Denosumab-Granted-prnews-1368953212.html?x=0&.v=1 Formal approval by the EU Commission was a fait accompli following the CHMP endorsement of Prolia in Dec 2009 (#msg-44690591).